MedTrace Logo

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT05673109 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-01-25

No results posted yet for this study

Summary

This clinical trial is evaluating a drug called AC176 in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least one prior systemic therapy.

The main goals of this study are to:

Evaluate the safety and tolerability of AC176, evaluate pharmacokinetics and preliminary antitumor activity of AC176

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

AC176

AC176 will be given orally (PO) on a 28-day cycle.

Sponsors & Collaborators

  • Accutar Biotechnology Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-22
Primary Completion
2023-10-08
Completion
2023-10-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05673109 on ClinicalTrials.gov